Pain Management in Small Animals: Common Drugs and Dosage Guidelines

Veterinary pain management is a cornerstone of compassionate care for dogs and cats, ensuring better outcomes, improved quality of life, and stronger veterinarian-client relationships. The 2022 AAHA Pain Management Guidelines for Dogs and Cats provide an updated framework for assessing and treating both acute and chronic pain in small animals. This blog explores key aspects of veterinary pain management, with a strong emphasis on common pharmacologic agents. While the guidelines emphasize a proactive, preemptive, and multimodal approach, they highlight the importance of tailoring treatments to individual patients. Note that specific dosages should always be determined based on product labels, patient factors, and veterinary oversight, as the guidelines do not provide exhaustive dosing details but prioritize evidence-based efficacy.

1. The Importance of Veterinary Pain Management in Small Animals

In veterinary pain management, recognizing and addressing pain early is essential to prevent it from becoming chronic and more resistant to treatment. Pain in dogs and cats can stem from surgery, injury, osteoarthritis (OA), or other conditions, affecting up to 40% of dogs and over 50% of cats with OA-related issues. The guidelines advocate shifting from reactive "damage control" to proactive strategies, including preemptive analgesia before procedures or disease progression.

Effective veterinary pain management involves the entire practice team and pet owners, using validated assessment tools like the Feline Grimace Scale or Canine Brief Pain Inventory. By integrating pharmacologic and nonpharmacologic options, veterinarians can minimize side effects and optimize relief. This holistic approach not only alleviates suffering but also supports mobility, sleep, and daily activities, enhancing health-related quality of life (HRQoL).

2. Principles of Multimodal Veterinary Pain Management

Veterinary pain management thrives on a multimodal strategy, combining multiple therapies to target different pain pathways and reduce reliance on any single drug. The guidelines outline a tiered decision tree: Tier 1 includes the most efficacious options like NSAIDs and opioids; Tier 2 adds adjuncts such as ketamine or alpha-2 agonists; and Tier 3 covers less proven modalities.

For acute pain, such as perioperative cases, start with opioids, NSAIDs, and local anesthetics alongside cold therapy and nursing care. In chronic pain, particularly musculoskeletal OA, prioritize COX-inhibiting NSAIDs or non-COX options like prostaglandin receptor antagonists. This tiered system ensures balanced, evidence-based veterinary pain management, adapting to canine and feline differences—cats often require owner-reported behavioral assessments due to subtle signs.

3. Common Drugs for Acute Pain in Veterinary Pain Management

Acute pain, often from surgery or trauma, demands rapid, preemptive intervention in veterinary pain management. Opioids form the backbone of Tier 1 treatments, providing reliable perioperative relief. Buprenorphine formulations like Simbadol are licensed for cats as a 24-hour subcutaneous injection, offering extended coverage ideal for at-home recovery. In dogs, similar uses are supported by studies, though not yet licensed.

NSAIDs, such as robenacoxib (Onsior), have expanded approvals for perioperative use in both species—oral tablets for cats (up to 3 days initially) and injectable forms since 2015. Robenacoxib is now also approved for dogs. Local anesthetics are highlighted as the most effective option; Nocita, a liposome-encapsulated bupivacaine, provides up to 3 days of wound-site analgesia post-orthopedic surgery in dogs or onychectomy in cats.

Adjuncts in Tier 2 include ketamine for its NMDA antagonism and alpha-2 agonists like dexmedetomidine for synergy with local blocks. Tramadol's role has diminished due to poor oral efficacy in dogs, though injectable forms show promise in cats. Gabapentin is commonly used but lacks strong data for acute canine pain. Always monitor for side effects like hyperthermia in cats with opioids.

4. Pharmacologic Options for Chronic Pain in Veterinary Pain Management

Chronic pain, especially OA, requires long-term veterinary pain management focused on Tier 1 drugs for sustained efficacy. COX-inhibiting NSAIDs are first-line, with several approved for dogs, including carprofen and meloxicam. Studies show no increased toxicity with prolonged use and a trend toward better pain control. Grapiprant (Galliprant), a non-COX EP4 receptor antagonist, was approved in 2016 for canine OA, blocking pain signals without altering prostaglandin production—efficacious in trials with 131 dogs and a favorable safety profile.

For cats, no NSAIDs are FDA-approved for long-term use in the US, but meloxicam and robenacoxib are approved elsewhere for musculoskeletal pain, with recent safety data in older cats, including those with kidney disease. Anti-nerve growth factor (NGF) monoclonal antibodies (mABs) like frunevetmab are a breakthrough, approved in the US for feline degenerative joint disease-associated pain, showing mobility improvements in pilot studies.

Tier 2 adjuncts include amantadine, effective with NSAIDs for OA (twice-daily dosing suggested by pharmacokinetics, though once-daily was used in original trials). Gabapentin is widely prescribed anecdotally for both species but has limited evidence; in cats, it may aid OA but causes sedation and reduced activity. Avoid long-term oral opioids due to poor absorption in dogs and abuse potential. Acetaminophen is inferior to NSAIDs like carprofen when combined with hydrocodone for OA.

5. Adjunctive and Emerging Drugs in Veterinary Pain Management

In veterinary pain management, adjunctive drugs in Tiers 2 and 3 enhance primary therapies for refractory cases. Alpha-2 agonists like dexmedetomidine provide perioperative analgesia, vasodilation mitigation, and sedation, with micro-infusions improving respiration. Maropitant (Cerenia), an NK1 receptor antagonist, excels as an antiemetic and offers weak visceral analgesia.

Emerging options include intra-articular (IA) injections: corticosteroids or biologics like platelet-rich plasma for localized OA in dogs, though data are mixed and less practical in cats. TRPV1 agonists (e.g., capsaicin) show promise for augmenting perioperative control. Anti-NGF mABs are expanding, with approvals in Europe and the US for cats, targeting OA pain drivers.

Cannabinoids lack robust data due to regulatory issues, showing mixed results. Tramadol is relegated to Tier 3 for dogs (ineffective orally) and cats (taste aversion). Steroids or acetaminophen serve as alternatives to NSAIDs in intolerant patients, but evidence is sparse. Disease-specific therapies, like bisphosphonates for osteosarcoma, fit Tier 2.

6. Integrating Nonpharmacologic Modalities and Best Practices in Veterinary Pain Management

While drugs dominate veterinary pain management, nonpharmacologic options in the guidelines complement them, especially for chronic pain. Tier 1 includes omega-3 fatty acid-enriched diets (proven analgesic in dogs), weight optimization (lean body condition slows OA progression), exercise (protective for hip dysplasia), and environmental modifications (ramps for cats' vertical access).

Rehabilitation therapy—encompassing manual techniques, laser therapy, and hydrotherapy—is recommended for acute and chronic cases, though evidence is limited. Cold therapy reduces nociceptor activation and edema post-surgery. Acupuncture shows promise postoperatively but not for canine OA.

Best practices emphasize team roles: veterinarians lead assessments, technicians handle education and follow-ups, and owners monitor behaviors. Reevaluate every 3-6 months, adjusting plans proactively. Client education via videos and demos boosts compliance. By blending these with drugs like NSAIDs and opioids, veterinary pain management achieves optimal, patient-centered care. Consult the full 2022 AAHA guidelines for detailed tools and always prioritize evidence-based, multimodal strategies.